{"entity": "journal", "iuid": "2edaeb222b5d49df831f31c58c092b55", "timestamp": "2026-08-20T20:36:36.418Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Mol%20Ther%20Oncol.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Mol%20Ther%20Oncol"}}, "title": "Mol Ther Oncol", "issn": "2950-3299", "issn-l": null, "publications_count": 2, "publications": [{"entity": "publication", "iuid": "c58636dfc2c94d12a6ba1c10e6f64c32", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c58636dfc2c94d12a6ba1c10e6f64c32.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c58636dfc2c94d12a6ba1c10e6f64c32"}}, "title": "Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.", "authors": [{"family": "Fletcher", "given": "Erika A K", "initials": "EAK"}, {"family": "Cordfunke", "given": "Robert A", "initials": "RA"}, {"family": "Nasi", "given": "Aikaterini", "initials": "A"}, {"family": "T\u00f6rnqvist", "given": "Gunilla", "initials": "G"}, {"family": "Valentijn", "given": "Rob R P M", "initials": "RRPM"}, {"family": "Bergqvist", "given": "Anna", "initials": "A"}, {"family": "Westhrin", "given": "Marita", "initials": "M"}, {"family": "Rasch", "given": "Wenche", "initials": "W"}, {"family": "Lindqvist", "given": "Frida", "initials": "F"}, {"family": "Dillmann", "given": "Inken", "initials": "I"}, {"family": "Lord", "given": "Martin", "initials": "M"}, {"family": "Bouwman", "given": "Neanke", "initials": "N"}, {"family": "Neefjes", "given": "Jacques J", "initials": "JJ"}, {"family": "Franken", "given": "Kees L M C", "initials": "KLMC"}, {"family": "McArdle", "given": "Stephanie", "initials": "S"}, {"family": "Ahmad", "given": "Murrium", "initials": "M"}, {"family": "Johansson", "given": "Silvia", "initials": "S"}, {"family": "Ossendorp", "given": "Ferry", "initials": "F"}, {"family": "Haggman", "given": "Michael", "initials": "M"}, {"family": "Lampinen", "given": "Maria", "initials": "M"}, {"family": "Ullenhag", "given": "Gustav", "initials": "G"}, {"family": "Ladjevardi", "given": "Sam", "initials": "S"}, {"family": "Leja-Jarblad", "given": "Justyna", "initials": "J"}, {"family": "Lilleby", "given": "Wolfgang", "initials": "W"}, {"family": "Drijfhout", "given": "Jan Wouter", "initials": "JW"}, {"family": "Mangsbo", "given": "Sara M", "initials": "SM"}], "type": "journal article", "published": "2025-06-18", "journal": {"title": "Mol Ther Oncol", "issn": "2950-3299", "volume": "33", "issue": "2", "pages": "200954", "issn-l": null}, "abstract": "Peptide-based vaccines can be used to deliver tumor-specific antigens to dendritic cells (DCs), leading to tumor-directed T cell responses. We previously developed a peptide-peptide conjugate technology enabling in vivo cross-linking of pre-existing tetanus toxin-directed antibodies, facilitating antigen delivery to, and activation of DCs. To achieve this, multiple identical tetanus toxin-derived B cell epitopes (MTTEs) are conjugated to synthetically produce target antigens of choice. Herein, we describe the generation of a prostate cancer vaccine candidate (TENDU) based on this technology. It includes long synthetic peptides harboring epitopes (CD4 and CD8) from prostate-specific antigen (PAP) and prostate-specific membrane antigen (PSMA). The preclinical efficacy of TENDU was assessed in experimental systems, and safety was evaluated in a rabbit toxicity study and a human whole blood loop assay. We also report the first clinical safety assessment of TENDU. Experimental studies showed that prostate cancer patients mounted anti-MTTE antibodies in response to tetanus vaccination with recall T cell responses detected in two patients. Transgenic humanized HLA-DR4 mice displayed T cell responses and increased anti-MTTE IgG levels after vaccination with a peptide construct including an HLA-DR4 epitope. The vaccine candidate was found safe, and a positive correlation between T cell responses and anti-MTTE antibodies was noted in the first-in-human study.", "doi": "10.1016/j.omton.2025.200954", "pmid": "40520577", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12166800"}, {"db": "pii", "key": "S2950-3299(25)00023-2"}], "notes": [], "created": "2026-08-20T08:02:59.054Z", "modified": "2026-08-20T08:02:59.086Z"}, {"entity": "publication", "iuid": "8c24315a16234e848c4c24fb875084ea", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8c24315a16234e848c4c24fb875084ea.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8c24315a16234e848c4c24fb875084ea"}}, "title": "Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.", "authors": [{"family": "Piki", "given": "Emilia", "initials": "E"}, {"family": "Dini", "given": "Alice", "initials": "A"}, {"family": "Rantanen", "given": "Frida", "initials": "F"}, {"family": "Bentz", "given": "Franziska", "initials": "F"}, {"family": "Paavolainen", "given": "Lassi", "initials": "L"}, {"family": "Barker", "given": "Harlan", "initials": "H"}, {"family": "Raivola", "given": "Juuli", "initials": "J"}, {"family": "Hirasawa", "given": "Akira", "initials": "A"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Murum\u00e4gi", "given": "Astrid", "initials": "A"}, {"family": "Ungureanu", "given": "Daniela", "initials": "D"}], "type": "journal article", "published": "2024-12-19", "journal": {"title": "Mol Ther Oncol", "issn": "2950-3299", "volume": "32", "issue": "4", "pages": "200903", "issn-l": null}, "abstract": "Patients with ovarian cancer, especially the high-grade serous ovarian cancer (HGSOC) subtype, face poor prognosis due to late diagnosis and treatment resistance. Owing to the high heterogeneity of HGSOC, identifying the origin of the disease and optimal treatments is difficult. Here, we characterized two primary immortalized human ovarian cell lines, human ovarian surface epithelium (HOSE)1C and HOSE2C, comparing their molecular profiling with representative HGSOC cells. We identified molecular features associated with normal and malignant phenotype of ovarian cells by applying single-cell transcriptomics, high-content image-based cell painting, and high-throughput drug testing. Our findings reveal distinct transcriptomic and morphological profiles for the two HOSEs, with a stromal phenotype. Moreover, their responses to the tumor microenvironment differ, exemplified by STAT1 and GREM1 upregulation in HOSE1C and HOSE2C, respectively. We identified selective activation of ERK/MEK targeted inhibitors in cancer cells compared to HOSEs. This study offers insights into the normal and malignant ovarian cells, shedding light on cancer development and drug responses.", "doi": "10.1016/j.omton.2024.200903", "pmid": "39634630", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11616607"}, {"db": "pii", "key": "S2950-3299(24)00145-0"}], "notes": [], "created": "2026-08-20T08:02:57.049Z", "modified": "2026-08-20T08:02:57.105Z"}], "created": "2026-08-20T08:02:57.065Z", "modified": "2026-08-20T08:02:57.065Z"}